Physician profile
Sadra Thomas
NPI 1528725637
$7,479.82
in general payments reported to CMS, 2019-2025
25 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $182 · 2022: $2,176 · 2023: $1,975 · 2024: $1,966 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,951 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,951.49 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,872.55 | 2021-2025 | |
| Amgen INC. | $1,233.37 | 2022-2025 | Tavneos, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $540.04 | 2022-2025 | |
| Glaxosmithkline, LLC. | $527.86 | 2022-2025 | Benlysta |
| Actelion Pharmaceuticals US, INC. | $410.58 | 2023-2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $408.07 | 2022-2025 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $373.57 | 2021-2025 | Saphnelo |
| Pfizer INC. | $359.84 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $292.00 | 2022-2024 | Acthar |
| Horizon Therapeutics Plc | $287.80 | 2022-2023 | Krystexxa |
| Lilly USA, LLC | $247.73 | 2022-2025 | Taltz, Olumiant |
| Genzyme Corporation | $165.23 | 2023-2025 | |
| Janssen Biotech, INC. | $160.46 | 2021-2025 | Tremfya |
| Aurinia Pharma U.S., INC. | $108.28 | 2021-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $88.47 | 2022-2025 | Strensiq, Ultomiris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $64.70 | 2021-2024 | Crysvita |
| Ucb, INC. | $63.78 | 2024-2025 | Bimzelx |
| Ani Pharmaceuticals, INC. | $60.57 | 2022-2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.46 | 2024 | Ofev, Spevigo |
| Octapharma USA, INC. | $40.40 | 2022 | |
| Genentech USA, INC. | $34.20 | 2022-2023 | Ocrevus |
| Biogen, INC. | $24.97 | 2021 | |
| Sobi, INC | $21.61 | 2022 | |
| Mylan Institutional INC. | $20.46 | 2023 | Hulio |
| Bioventus LLC | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadra Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.